Vittoria Biotherapeutics Highlights Novel CAR-T Cell Therapy Approach at ASH 2024

Vittoria Biotherapeutics, a Philadelphia-based clinical-stage immunotherapy company, showcased preclinical findings at the 66th Annual American Society of Hematology (ASH) Meeting.

Continue ›››

Lantern Pharma Enrolls First Patient in Taiwan for Phase 2 Trial for Never-Smoker Lung Cancer

Following its recent expansion into Japan, Lantern Pharma has now dosed the first patient in Taiwan as part of its …

Continue ›››

IDEAYA Demonstrates Preclinical Success with PRMT5 Inhibitor IDE892

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a clinical-stage precision medicine oncology company, announced the nomination of IDE892, a potent and selective …

Continue ›››

Cherry Biotech Publishes Research on Advanced Skin-on-Chip Model in Microfluidics

Cherry Biotech has announced the publication of research on its CubiX platform in Advanced Healthcare Materials. The study explores a …

Continue ›››

Antag Therapeutics Secures €80 Million to Advance GIPR-Based Obesity Therapies

Following the FDA’s October 2024 clearance of Antag Therapeutics’ Investigational New Drug (IND) application for its lead molecule, AT-7687, the …

Continue ›››

AI Proteins Announces Collaboration with Bristol Myers Squibb for Miniprotein Therapeutics Worth Up to $400 Million

AI Proteins, Inc., a biotechnology company specializing in the computational design of therapeutic miniproteins, announced a research collaboration and option …

Continue ›››

Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Rare Diseases and Oncology

Unnatural Products, Inc. a California-based biotech company specializing in AI-enabled massively parallel chemistry to develop orally bioavailable macrocyclic peptides, announced …

Continue ›››

GE HealthCare to Acquire Full Ownership of Nihon Medi-Physics from Sumitomo Chemical

GE HealthCare (NASDAQ: GEHC) announced an agreement to acquire Sumitomo Chemical’s 50% stake in Nihon Medi-Physics Co., Ltd. (NMP), assuming …

Continue ›››

Recursion Begins First-in-Human Trial for AI-Discovered Protein Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

In October 2024, Recursion Pharmaceuticals received FDA clearance to initiate clinical trials for REC-1245, an investigational RBM39 degrader targeting biomarker-enriched …

Continue ›››

Insilico Medicine Celebrates Its 10th AI-Driven Drug Candidate to Get FDA IND Clearance

Insilico Medicine has announced FDA IND clearance for ISM5939, marking the 10th AI-designed drug candidate from the company to enter …

Continue ›››

Brainomix Wins Two Awards for AI Imaging Technology

Brainomix has been named the LSX European Lifestars “Healthtech Company of the Year” and the OBN “Most Transformative Healthtech Company …

Continue ›››

Raidium Secures €16 Million to Advance Radiology Foundation Model

Raidium, a french start-up building a radiology-focused artificial intelligence, has raised €16 million in seed funding co-led by Newfund and …

Continue ›››